Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
- Written by PR Newswire
- IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life
- IMG-007 has demonstrated a favorable safety profile, consistent with a silenced ADCC function via bioengineering
- IMG-007 is being evaluated in two global proof-of-concept trials
SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Inmagene...














